Strengthening and regenerating heart valves
By using biodegradable support rings and surrounding walls in the heart valves, the collapse of traditional valves under strong blood pressure and pulsating pressure is solved, and the valve regeneration and adaptation is promoted, achieving a long-term solution for heart valve replacement.
Patent Information
- Application Number
- CN202080021587.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-02-04
- Filing Date
- 2020-01-30
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-01-30
AI Technical Summary
Traditional heart valve replacement valves have limitations in growth and adaptation, especially when they are subjected to strong blood pressure and pulsating pressure, and are difficult to adapt to children's growth needs.
Using a reinforced regenerating heart valve device, providing structural stiffness and support through a biodegradable support ring and surrounding wall, the support ring is attached to the base of the valve and degrades after implantation, and bioactive molecules are coated around the inner side of the wall to promote regeneration and differentiation .
Effectively maintain the shape of the valve, prevent collapse, promote host cell migration and regeneration, adapt to forces within the aortic roots, reduce inflammation and immune-mediated destruction, prolong valve life and adapt to growth needs.
Smart Images

Figure CN113573668B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Application No. 62 / 800,853, filed February 4, 2019, which is incorporated herein by reference in its entirety for all purposes. Technical Field
[0003] This application relates generally to regenerative heart valves and more particularly to enhanced regenerative heart valves for use in heart valve replacement. Background Art
[0004] Valvular stenosis and regurgitation are several complications that may require heart valve replacement. Conventional replacement valves are constructed from a variety of biocompatible metals, polymers, and animal pericardial tissue. These valve prostheses often have known limitations, including lifelong use of blood thinners, a 10-20 year valve life expectancy, and / or an inability to grow with a child. Therefore, there is a need for a heart valve that can grow and integrate within the replacement site.
[0005] Regenerative tissue heart valves are an attractive solution that overcomes the limitations of traditional replacement valves. Regenerative tissue heart valves are bioengineered valves produced in vitro. Because regenerative valves are living, growing tissue, the valves have plasticity and remodeling capabilities that allow them to bind and grow at the replacement site. Based on these qualities, regenerative tissue valves are an ideal choice for procedures requiring valve replacement. Summary of the invention
[0006]
[0013] Many embodiments relate to devices and methods for enhancing regenerated heart valves.
[0007] In one embodiment, an implantable device for heart valve replacement includes a regenerative heart valve, which includes regenerative tissue and a first ring structure, wherein the first ring structure is suitable for being located at the base of the heart valve to provide support for the regenerative tissue so that when the heart valve is located at the replacement site, the regenerative tissue can grow and combine with natural tissue while maintaining the valve shape of the heart valve.
[0008] In another embodiment, an implantable device for heart valve replacement further comprises a first tissue layer encasing the first ring structure, such that the first tissue layer reduces exposure of the first ring structure to native surrounding tissue when positioned at the replacement site.
[0009] In yet another embodiment, the heart valve is an aortic valve and the first ring structure provides sufficient support to enable the regenerated tissue to grow in the presence of forces occurring at the native aortic root.
[0010] In further embodiments, the first ring structure is further adapted to expand as the heart valve annulus expands.
[0011] In yet another embodiment, the first ring structure is segmented into at least one segment having two overlapping ends that allow for expansion.
[0012] In still further embodiments, the two overlapping ends are fastened together using a pin on the first end and a receiving guide on the second end.
[0013] In yet a further embodiment, the pin has a pin head extending orthogonally from the first end, and the guide has a hollow portion configured to fit the pin head, and wherein the guide further has a hole allowing the pin to move in one direction so that the two ends move in opposite directions.
[0014] In yet further embodiments, the first ring structure is an overlapping coiled ring.
[0015] In yet further embodiments, the first ring structure is a compression ring helical spring.
[0016] In yet further embodiments, the first loop structure is constructed of a biodegradable material.
[0017] In yet a further embodiment, the biodegradable material is selected from the group consisting of polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB), and polycaprolactone (PCL).
[0018] In yet further embodiments, the biodegradable material is designed to degrade within approximately a timeframe selected from the group consisting of: 6, 12, 18, 24, 30, and 36 months.
[0019] In yet further embodiments, the first tissue layer is adapted to capture degradation particles of the first ring structure.
[0020] In yet further embodiments, the first ring structure is constructed of a metallic material.
[0021] In yet a further embodiment, the metal material is selected from the group consisting of: stainless steel, cobalt-chromium alloy, titanium, and titanium alloy.
[0022] In yet further embodiments, the first ring structure is attached to the base of the heart valve, and wherein the attachment is provided by sutures or an adhesive.
[0023] In yet a further embodiment, the second ring structure is adapted to be located on the effluent side of the heart valve to provide support for the regenerated tissue so that when the heart valve is located at the replacement site, the regenerated tissue can grow and combine with the natural tissue while maintaining the valve shape of the heart valve; and the second tissue layer wraps the second ring structure, wherein when located at the replacement site, the second tissue layer reduces exposure of the first ring structure to the natural surrounding tissue.
[0024] In yet further embodiments, the second ring is expandable.
[0025] In yet further embodiments, the tissue sleeve is formed from pericardial tissue derived from an animal source.
[0026] In yet further embodiments, the tissue sleeve is formed from autologous tissue derived from the individual to be treated.
[0027] In yet further embodiments, tissue for regenerating a heart valve is formed in vitro.
[0028] In yet further embodiments, the tissue of the regenerated heart valve is formed from autologous tissue derived from the individual to be treated.
[0029] In yet further embodiments, the tissue of the regenerated heart valve is grown as a biodegradable scaffold.
[0030] In yet further embodiments, the biodegradable scaffold is made of a material selected from the group consisting of collagen, chitosan, decellularized extracellular matrix, alginate, and fibrin.
[0031] In yet further embodiments, the regenerated heart valve is trained in a bioreactor system that simulates the physiological and mechanical pressures that occur in the aortic root.
[0032] In yet further embodiments, the tissue for regenerating a heart valve is grown from a cell source selected from the group consisting of mesenchymal stem cells, cardiac progenitor cells, endothelial progenitor cells, adipose tissue, vascular tissue, amniotic fluid-derived cells, and cells differentiated from pluripotent stem cells.
[0033] In yet a further embodiment, the cell source is mesenchymal stem cells derived from human bone marrow.
[0034] In yet further embodiments, the source of cells is vascular tissue derived from a peripheral artery or umbilical vein.
[0035] In yet further embodiments, the tissue of the regenerated heart valve is incorporated with bioactive molecules.
[0036] In yet further embodiments, the biomolecule promotes regeneration and differentiation.
[0037] In yet a further embodiment, the biomolecule is selected from: vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), insulin-like growth factor 1 (IGF-1) and stromal derived factor-1-α (SDF-1-α).
[0038] In yet further embodiments, the biomolecule reduces inflammation and immune-mediated destruction of the regenerated valve.
[0039] In one embodiment, an implantable device for supporting tissue regeneration at a heart valve includes a regenerative heart valve, which includes regenerated animal tissue and a tubular wall, which is suitable for being positioned (situated) to surround the outflow side of the regenerated heart valve when implanted in an individual, and the tubular wall is further suitable for providing rigid support for the regenerated heart valve so that when located on the outflow side of the heart valve, the regenerated tissue can grow and integrate with natural tissue while maintaining the valve shape of the heart valve.
[0040] In another embodiment, the heart valve is an aortic valve and the tubular wall provides sufficient support to enable the regenerated tissue to grow in the presence of forces occurring in the native aortic root.
[0041] In yet another embodiment, the internal face of the tubular wall is modified to promote regeneration of the regenerated heart valve and native surrounding tissue.
[0042] In further embodiments, the inner side of the tubular wall has a conformal pattern comprising a set of ridges or grooves that are spaced apart to enable alignment and patterning of regenerative cells to help form an endothelial-like tissue layer.
[0043] In yet another embodiment, the set of ridges or grooves are offset by a distance that is greater than the average size of cells associated with pannus formation.
[0044] In yet further embodiments, the inner side is coated or impregnated with biologically active molecules.
[0045] In yet further embodiments, the bioactive molecule promotes angiogenesis and differentiation.
[0046] In yet further embodiments, the bioactive molecule attracts native endothelial progenitor cells.
[0047] In yet a further embodiment, the biologically active molecule is selected from: vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), insulin-like growth factor 1 (IGF-1) and stromal derived factor-1-α (SDF-l-α).
[0048] In yet further embodiments, the biomolecule reduces inflammation and immune-mediated destruction of the regenerated valve.
[0049] In yet further embodiments, biological cells are incorporated into or coated onto the inner side.
[0050] In yet further embodiments, the cells are derived from an autologous source.
[0051] In yet further embodiments, the cells are derived from a source selected from the group consisting of mesenchymal stem cells, cardiac progenitor cells, endothelial progenitor cells, adipose tissue, vascular tissue, amniotic fluid-derived cells, and cells differentiated from pluripotent stem cells.
[0052] In yet a further embodiment, the cell source is mesenchymal stem cells derived from human bone marrow.
[0053] In yet further embodiments, the source of cells is vascular tissue derived from a peripheral artery or umbilical vein.
[0054] In yet further embodiments, the tubular wall is attached to the regenerative heart valve, and wherein the attachment is provided by sutures or an adhesive.
[0055] In yet further embodiments, the tubular wall is constructed of a biodegradable material.
[0056] In yet a further embodiment, the biodegradable material is selected from the group consisting of polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB), and polycaprolactone (PCL).
[0057] In yet further embodiments, the biodegradable material is designed to degrade within a period of time selected from the group consisting of: 6, 12, 18, 24, 30, and 36 months.
[0058] In yet further embodiments, tissue for regenerating a heart valve is formed in vitro.
[0059] In yet further embodiments, the tissue of the regenerated heart valve is formed from autologous tissue derived from the individual to be treated.
[0060] In yet further embodiments, the tissue of the regenerated heart valve is grown as a biodegradable scaffold.
[0061] In yet further embodiments, the biodegradable scaffold is made of a material selected from the group consisting of collagen, chitosan, decellularized extracellular matrix, alginate, and fibrin.
[0062] In yet further embodiments, the regenerated heart valve is trained in a bioreactor system that simulates the physiological and mechanical pressures that occur in the aortic root.
[0063] In yet further embodiments, the tissue for regenerating a heart valve is grown from a cell source selected from the group consisting of mesenchymal stem cells, cardiac progenitor cells, endothelial progenitor cells, adipose tissue, vascular tissue, amniotic fluid-derived cells, and cells differentiated from pluripotent stem cells.
[0064] In yet a further embodiment, the cell source is mesenchymal stem cells derived from human bone marrow.
[0065] In yet further embodiments, the source of cells is vascular tissue derived from a peripheral artery or umbilical vein.
[0066] In yet further embodiments, the tissue of the regenerated heart valve is incorporated with bioactive molecules.
[0067] In yet further embodiments, the biomolecule promotes regeneration and differentiation.
[0068] In yet a further embodiment, the biomolecule is selected from: vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), insulin-like growth factor 1 (IGF-1) and stromal derived factor-1-α (SDF-1-α).
[0069] In yet further embodiments, the biomolecule reduces inflammation and immune-mediated destruction of the regenerated valve.
[0070] Additional embodiments and features are partially set forth in the following description, and in part will become apparent to those skilled in the art after examining the specification or may be learned through practice of the invention. A further understanding of the nature and advantages of the invention may be achieved by reference to the remainder of the specification and the accompanying drawings, which constitute a part of this disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] The description and claims will be more fully understood with reference to the following drawings, which are presented as exemplary embodiments of the invention and should not be construed as a complete recitation of the scope of the invention.
[0072] Figure 1A Perspective views illustrating embodiments of a regenerative heart valve having a support ring are provided.
[0073] Figure 1B An elevation view illustrating an embodiment of a regenerative heart valve having a support ring is provided.
[0074] Figure 2A An elevation view illustrating an embodiment of a regenerative heart valve having a support ring and a tissue sleeve is provided.
[0075] Figure 2B Cross-sectional views illustrating embodiments of a regenerative heart valve having a support ring and a tissue sleeve are provided.
[0076] Figure 3 Perspective views illustrating embodiments of a regenerative heart valve having multiple support rings are provided.
[0077] Figure 4 A top view of an example segmented ring implementation is provided.
[0078] Figure 5 An elevation view of an embodiment of a joint between two ends of an example segmented ring is provided.
[0079] Fig. 6A An exploded perspective view illustrating an embodiment of a joint between two ends secured using a pin and guide for use with a segmented ring is provided.
[0080] Figure 6B A top view illustrating an embodiment having an end of a guide for use with a segmented ring is provided.
[0081] Figure 7 A top view of an example coiled ring implementation is provided.
[0082] Figure 8 A top view of an embodiment of an example annular spiral spring ring is provided.
[0083] Fig.9A Perspective views illustrating embodiments of a regenerative heart valve having a surrounding support wall are provided.
[0084] Fig. 9B A cut-out perspective view illustrating an embodiment of a regenerative heart valve having a surrounding support wall is provided. DETAILED DESCRIPTION
[0085] Turning now to the accompanying drawings, devices and methods for providing reinforced support for a regenerative heart valve are described according to various embodiments of the present invention. Several embodiments relate to reinforcing elements to provide support to the regenerative heart valve, particularly when implanted in the aortic root. According to several embodiments, the reinforcing elements provide structure and rigidity to withstand the stresses occurring in the aortic root, where the forces associated with systolic and diastolic pressures are strong and repetitive. In many embodiments, the reinforcing elements prevent and / or mitigate collapse of the regenerative heart valve. In some embodiments, the reinforcing elements help the regenerative heart valve maintain its shape in the aortic root after implantation.
[0086] In many embodiments, the reinforcing element is biodegradable. According to various embodiments, a variety of synthetic biodegradable polymers can be used to construct the support ring, including (but not limited to) polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB), and polycaprolactone (PCL). Several embodiments relate to reinforcing elements constructed of biocompatible metals or metal alloys (including but not limited to stainless steel, cobalt chromium alloys, titanium, and titanium alloys).
[0087] In many embodiments, the support ring is attached to the base of the regenerated heart valve to strengthen the valve. In several embodiments, the support ring is wrapped in a tissue sleeve to provide a barrier between the ring and the native tissue when implanted. In some embodiments, the support ring is expandable.
[0088] In various embodiments, a tubular wall is provided surrounding the regenerated heart valve such that the wall provides structural support. In some embodiments, the surrounding wall promotes regeneration of the native luminal wall within the heart valve and / or aortic root.
[0089] The described devices, systems, and methods should not be construed as limiting in any way. Rather, the present disclosure is directed to all novel and non-obvious features and aspects of the various disclosed embodiments, individually and in various combinations and sub-combinations with each other. The disclosed methods, systems, and apparatus are not limited to any specific aspect, feature, or combination thereof, nor do the disclosed methods, systems, and apparatus require the presence of any one or more specific advantages or problems to be solved.
[0090] Although the operations of some disclosed methods are described in a particular, sequential order for ease of presentation, it should be understood that such description includes rearrangement unless the specific language set forth below requires a particular ordering. For example, the operations described sequentially may be rearranged or performed simultaneously in some cases. In addition, for simplicity, the accompanying drawings may not show the various ways in which the methods, systems, and apparatus disclosed therein may be used in conjunction with other systems, methods, and apparatuses.
[0091] Regenerative heart valve reinforced with support ring
[0092] Several embodiments relate to support rings for strengthening a regenerated heart valve. According to several embodiments, the support ring provides structure and rigidity to withstand stresses occurring within the aortic root, where forces associated with systolic and diastolic pressures are strong and repeated. In many embodiments, the support ring prevents and / or mitigates collapse of the regenerated heart valve. In some embodiments, the support ring helps the regenerated heart valve maintain its shape within the aortic root after implantation.
[0093] For the embodiment of the regenerative heart valve (101), FIG. 1A provides a stereoscopic view and Figure 1B Provided is a front view of a regenerative heart valve (101) having an attachment ring (103) for reinforcement. According to several embodiments, the heart valve (101) and the attachment ring (103) will be used as a heart valve replacement to treat heart valve disease. Many embodiments relate to regenerative heart valves for replacing a malfunctioning aortic valve, however, it should be understood that the mitral valve, tricuspid valve, and pulmonary valve may also be replaced. Blood flow through the heart valve is depicted by arrows 105.
[0094] As can be seen in the figure, an embodiment of the regenerative heart valve (101) has three leaflets (107a, 107b, and 107c) as the regenerated tissue. The leaflets are joined and / or abutted at the base (109) and the lateral commissures (111). Typically, two or three leaflets are formulated in the regenerative heart valve, but it should be understood that the number of leaflets can vary and still fall within some embodiments of the present disclosure.
[0095] When replacing the aortic valve, according to various embodiments, the replacement valve (101) should be positioned within the aortic root such that the base (109) and attachment ring (103) are located at the aortic valve annulus, the leaflet tops are located at the sinotubular junction, and blood flows following arrow 105 (e.g., from the left ventricle into the ascending aorta).
[0096] Multiple embodiments utilize regenerated tissue to form tissue portions of a regenerated heart valve (including leaflets). In some embodiments, the regenerated heart valve is grown in vitro prior to implantation according to methods understood in the art. For a more detailed discussion of regenerating heart valves, see the description described in the section labeled "Regenerating Heart Valves" provided herein.
[0097] In a plurality of embodiments, the regenerative heart valve will be inserted into the aortic root to replace the malfunctioning aortic valve, wherein the forces associated with systolic and diastolic pressures are strong and repeated. Because the regenerative heart valve is usually composed of soft tissue and has a high degree of plasticity, they usually lack sufficient rigidity to withstand strong pulsating pressures. Therefore, the implanted regenerative heart valve may collapse, thereby causing serious damage and preventing the valve from being properly incorporated into the aortic root. Further growth and regeneration in the aortic root may also be inhibited because the host cells will not have the ability to migrate and assimilate in the regenerative valve. Therefore, several embodiments relate to providing a reinforcing support ring that provides a structural rigidity capable of withstanding the contractile force and pulsating force associated with the blood pressure in the aortic root. In many embodiments, the reinforcing support ring maintains the shape and functionality of the regenerative heart valve while withstanding the stress from the blood pressure force.
[0098] As in Figure 1A and 1B As depicted in the embodiments of the present invention, a biocompatible support ring (103) is attached to the base of the regenerated heart valve (101) at the base of the inflow side. In several embodiments, the support ring provides stiffness and support for the regenerated heart valve. In some embodiments, the support ring is capable of supporting the regenerated heart valve to withstand the forces within the aortic root so that the heart valve can maintain the valve shape and continue to regenerate and grow after implantation. Therefore, in some embodiments, the support ring has sufficient compressive strength to prevent the regenerated heart valve from collapsing due to the contractile forces within the aortic root. Similarly, in some embodiments, the support ring has sufficient fatigue strength so that the regenerated heart valve can withstand the pulsating pressure associated with contraction and diastole. As is known in the art, the pressure within the aortic root can be approximately 120 systolic mmHg in a typical human, and can reach above 150 systolic mmHg or even 180 systolic mmHg in individuals with severe hypertension. Thus, in various embodiments, the regenerated heart valve is capable of withstanding a pressure of at least 100 mmHg, 110 mmHg, 120 mmHg, 130 mmHg, 140 mmHg, 150 mmHg, 160 mmHg, 170 mmHg, or 180 mmHg.
[0099] In many embodiments, the support ring is biodegradable. According to various embodiments, a variety of synthetic biodegradable polymers can be used to construct the support ring, including (but not limited to) polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB) and polycaprolactone (PCL). It should be understood that a variety of materials can be combined to construct the support ring. In some embodiments, the support ring degrades after a period of time after implantation, which can allow host cells to migrate into the regenerated valve and approach the regenerated valve so that the host cells can support the valve after the ring is degraded. When the regenerated valve is converted into host living tissue and adapted to the local environment (including bearing the force in the aortic root), the ring will no longer be needed. In various embodiments, the biodegradable support ring will degrade within a period of 6 to 36 months. In some specific embodiments, the biodegradable support ring will degrade within approximately 6, 12, 18, 24, 30 or 36 months. It will be appreciated that the selected material and thickness of the biodegradable support ring may be selected such that the time period for degradation may be manipulated.
[0100] Several embodiments relate to support rings constructed of biocompatible metals or metal alloys, including, but not limited to, stainless steel, cobalt-chromium alloys, titanium, and titanium alloys. When utilizing a metal or metal alloy support ring, it is expected that the metal ring will remain in the regenerated valve and be incorporated into the host after implantation. In various embodiments, the metal or alloy support ring is durable and will not corrode over time, so that the host will not have problems with the ring. In some embodiments, a surface treatment and / or coating is performed on the metal or alloy support ring to resist corrosion. In some embodiments, the metal or alloy ring is suitable for removal at a certain point in time after implantation.
[0101] In various embodiments, the support ring is secured to the base of the regenerated heart valve on the inflow side. In some embodiments, the support ring is secured to the base of the regenerated heart valve using sutures. In some embodiments, the sutures used to secure the support ring to the base of the regenerated heart valve are bioabsorbable. In some embodiments, the support ring is secured to the base of the regenerated heart valve using a biocompatible adhesive.
[0102] In many embodiments, a tissue sleeve surrounds the support ring to isolate the support ring from the host's tissue at the implantation site. Figure 2A and 2BProvided in the figure are front and cross-sectional views of an embodiment of a regenerative heart valve (201) with a support ring (203) attached. Wrapping the support ring (203) is a tissue sleeve (205). It should be understood that according to a plurality of embodiments, any suitable support ring constructed of any suitable material is wrapped by the tissue sleeve. Therefore, in some embodiments, the tissue sleeve wraps a metal or metal alloy ring. And in some embodiments, the tissue sleeve wraps a biodegradable polymer.
[0103] In several embodiments, the tissue sleeve completely surrounds and encapsulates the support ring, which can provide a variety of benefits. In some embodiments, when a metal or metal alloy support ring is encapsulated by a tissue sleeve, the tissue sleeve protects the host from direct contact with the support ring after implantation. In some embodiments, when a biodegradable polymer support ring is encapsulated by a tissue sleeve, the tissue sleeve captures degradation fragments of the support ring, preventing the degradation fragments from entering the host's circulatory system.
[0104] According to many embodiments, the tissue sleeve package can be derived from any suitable tissue source. In some embodiments, regenerative tissue is utilized to form a tissue sleeve, which can be combined with the host's native tissue after implantation. In some embodiments, the same regenerative tissue used to form a regenerative heart valve is used to form a tissue sleeve. In some embodiments, the tissue sleeve is formed by pericardial tissue derived from an animal source (e.g., cattle, pigs).
[0105] According to various embodiments, the tissue sleeve is grown in vitro in the presence of the support ring, such that the tissue sleeve grows around the support ring to encase it. In some embodiments, the tissue sleeve is layered around the support ring and sutured to encase the support ring.
[0106] In multiple embodiments, the support ring wrapped in the tissue sleeve is fixed to the base of the regenerated heart valve on the inflow side. In some embodiments, the support ring is wrapped in a tissue sleeve that is fixed to the base of the regenerated heart valve using sutures. In some embodiments, the sutures used to fix the support ring wrapped in the tissue sleeve to the base of the regenerated heart valve are bioabsorbable. In some embodiments, the support ring wrapped in the tissue sleeve is fixed to the base of the regenerated heart valve using a biocompatible adhesive.
[0107] Various embodiments also relate to a plurality of support rings to provide support to the regenerated heart valve. Figure 3 Provided in the present invention is an embodiment of a regenerative heart valve (301) having two support rings (303a and 303b). In some embodiments, a second support ring is provided along the commissure of the regenerative heart valve to further support the valve. In some embodiments, further support is provided between the multiple support rings in the form of struts or wire mesh.
[0108] A number of embodiments relate to methods of delivering a support ring and / or a regenerative valve to a deployment site. As understood in the art, the methods may be performed on any suitable recipient, including but not limited to humans, other mammals (e.g., pigs), cadavers, or anthropomorphic mannequins. Thus, the delivery methods include treatment methods (e.g., treatment of human subjects) and training and / or practice methods (e.g., performing the methods using anthropomorphic mannequins that simulate the human vasculature). Delivery methods include but are not limited to open heart surgery and transcatheter delivery.
[0109] When using a transcatheter delivery system, any appropriate approach to the deployment site can be utilized, including, but not limited to, transfemoral, subclavian, transapical, or transaortic approaches. In several embodiments, a catheter containing a support ring and / or a regenerated valve is delivered to the deployment site via a guidewire. At the deployment site, according to many embodiments, the support ring and / or the regenerated valve are released from the catheter and then expanded into a form in which the support ring is located at the base of the regenerated heart valve. A variety of expansion mechanisms can be utilized, such as, for example, the use of an inflatable balloon, mechanical expansion, or a self-expanding device. Specific shape designs and radiopaque areas on the frame and / or cover can be used to monitor expansion and implementation.
[0110] The delivery and use of support rings and / or regenerative valves can be used in a variety of applications. In some embodiments, a support ring and / or regenerative device is delivered to a site for valve replacement, particularly aortic valve replacement.
[0111] Scalable ring structure
[0112] Multiple embodiments relate to expandable support rings. In several embodiments, as described herein, the support ring is a ring that supports the regenerated valve against stresses that occur within the aortic root. In some cases, it may be desirable for the support ring to expand as the aortic root expands. In many embodiments, the support ring provides an outward radial force to all of the rings to expand as the aortic root expands. This is particularly true in heart valve replacement surgeries in growing children. Therefore, in several embodiments, the support ring is expandable so that the support can expand as the regenerated valve and / or the native aortic root expands.
[0113] Figure 4Provided in the figure is an embodiment of an expandable segmented support ring (401). As shown, the segmented support ring (401) has three sections (403a, 403b and 403c), which allows for expandability at three joints (405a, 405b and 405c). The ability to expand at three joints is depicted by arrows (407a, 407b and 407c). However, it should be understood that the segmented support ring can have any appropriate number of sections and joints, but at least one section and one joint must be present. In various embodiments, the segmented support ring has 1, 2, 3, 4 or 5 sections and joints.
[0114] In several embodiments, the segments of the segmented support ring overlap at the joints. Figure 5 , provided is an elevated view of an embodiment of a joint (501) of a segmented support ring, wherein a first end of segment (503) and a second end of segment (505) overlap. When the first end (503) and the second end (505) move in opposite directions as depicted by arrows (507), the joint (501) expands and thus allows for expansion of the segmented ring. It should be noted that the ends (503 and 505) can be the ends of a single segment or the ends of two separate segments.
[0115] In many embodiments, overlapping segments of a segmented ring utilize pins and guides to secure the joint between the two segment ends, yet still allow for expansion. Fig. 6A 603 and 605. Provided in FIG. 604 is an exploded view of an embodiment of a joint (601) having a first end (603) and a second end (605) using a pin (607) and a guide (609). Note that the guide (609) is hollow within the first end (603). Figure 6B 603 and 605. Provided in FIG. 604 is a top-down view of a first end (603) having a guide (609) to receive a pin (607) of a second end. The pin (607) has a head (611) that is wider than the hole (613) of the guide (609) to secure the ends (603 and 605) together but still allow the ends to move in opposite directions as depicted by arrows (615). Expansion of the joint (601) allows the segmented ring to expand.
[0116] In many embodiments, the pin and guide are designed so that the pin head fits within the hollow portion of the guide, but is large enough that the pin head cannot pass through the hole of the guide. Thus, in some embodiments, the width of the pin head is wider than the width of the hole, and the width of the hollow portion of the guide is wider than the width of the pin head. Additionally, in some embodiments, the connecting arm of the pin fits within the hole of the guide so that the connecting arm can move freely in at least one direction to allow expansion. Note that the shape of the pin head and the hollow portion can vary, but should be designed to work in concert so that the pin head can move freely in at least one direction within the hollow portion. Thus, the pin head can be any suitable shape, including (but not limited to) spherical, cylindrical, and cubic.
[0117] Various embodiments contemplate a variety of annular shapes for the support ring with an outward radial force that allows expansion when the regenerated valve expands. Figure 7 Provided in the embodiments are overlapping coiled rings with outward radial forces. And in Figure 8 Provided in the drawings are embodiments of compression annular helical springs with outward radial forces. Although the various figures depict the expandable rings as segmented rings, overlapping helical rings, and annular helical springs, any suitable ring with outward radial forces that allow expansion may be used according to various embodiments.
[0118] In many embodiments, the expandable support ring is biodegradable. According to various embodiments, a variety of synthetic biodegradable polymers can be used to construct the support ring, including (but not limited to) polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB) and polycaprolactone (PCL). It should be understood that a variety of materials can be combined to construct the expandable support ring. In some embodiments, the expandable support ring degrades after implantation for a period of time, which allows host cells to migrate into the regenerated valve and close to the regenerated valve so that the host cells can support the valve after the ring is degraded. When the regenerated valve is converted into host living tissue and adapted to the local environment (including bearing the force in the aortic root), the ring will no longer be needed. In various embodiments, the biodegradable and expandable support ring will degrade within a period of 6 to 36 months. In some specific embodiments, the biodegradable and expandable support ring will degrade within approximately 6, 12, 18, 24, 30 or 36 months. It will be appreciated that the selected material and thickness of the biodegradable and expandable support ring may be selected so that the time period for degradation may be controlled.
[0119] Several embodiments relate to expandable support rings constructed of biocompatible metals or metal alloys, including, but not limited to, stainless steel, cobalt-chromium alloys, titanium, and titanium alloys. When utilizing a metal or metal alloy expandable support ring, it is expected that the metal ring will remain in the regenerated valve and be incorporated into the host after implantation. In various embodiments, the metal or alloy expandable support ring is durable and will not corrode over time, so that the host will not have problems with the ring. In some embodiments, a surface treatment and / or coating is performed on the metal or alloy expandable support ring to resist corrosion. In some embodiments, the metal or alloy ring is suitable for removal at a certain point in time after implantation.
[0120] In multiple embodiments, the expandable ring is fixed to the base of the regenerated heart valve on the inflow side to provide structural support. In some embodiments, the expandable support ring is fixed to the base of the regenerated heart valve using sutures. In some embodiments, the sutures used to fix the expandable ring to the base of the regenerated heart valve are bioabsorbable. In some embodiments, the expandable support ring is fixed to the base of the regenerated heart valve using a biocompatible adhesive. In several embodiments, the expandable support ring is attached to the base of the regenerated valve to provide structural support.
[0121] In many embodiments, the tissue sleeve completely surrounds and wraps the expandable support ring, which can provide multiple benefits. In some embodiments, when the metal or metal alloy support expandable ring is wrapped by the tissue sleeve, the tissue sleeve protects the host from direct contact with the support ring after implantation. In some embodiments, when the biodegradable polymer support ring is wrapped by the tissue sleeve, the tissue sleeve captures the degradation fragments of the support ring, preventing the degradation fragments from entering the host's circulatory system.
[0122] Heart valve with regeneration-promoting wall
[0123] Several embodiments relate to regenerative heart valves having a surrounding wall. In many embodiments, the surrounding wall provides structural rigidity such that it provides structural support to the regenerative heart valve so that it can withstand stresses occurring within the aortic root. In multiple embodiments, the surrounding wall promotes regeneration of the regenerative heart valve by supplying regenerative factors that promote migration and transformation of host cells within the implanted valve.
[0124] Fig.9A The stereogram is provided in Fig. 9B 1 is a perspective view with a cut-out window of an embodiment of a regenerative heart valve (901) having a surrounding wall (903). The surrounding wall (903) extends from the base region (905) of the valve to near or beyond the top of the leaflet (907).
[0125] In various embodiments, a regenerative heart valve having a surrounding wall is inserted into the aortic root to replace a dysfunctional aortic valve. The outer side (909) of the support wall (903) is designed so that it conforms to the natural luminal surface in the aortic root. The inner side (911) of the support wall can be etched to form grooves and / or coated with molecules to promote cell binding within the heart valve (901) and regeneration of the heart valve (901).
[0126] In various embodiments, the surrounding support wall provides structural support to the regenerated valve in the aortic root, wherein the force associated with systolic and diastolic pressures is very strong and repeated. Because regenerated heart valves are usually composed of soft tissue and have a high degree of plasticity, they lack sufficient rigidity to withstand strong pulsating pressures. Therefore, the newly implanted regenerated heart valve may be forced to collapse, causing serious damage and preventing the valve from correctly combining with the aortic root. Further growth and regeneration in the aortic root may also be inhibited because host cells will not have the ability to migrate and assimilate in the regenerated valve. Therefore, several embodiments relate to providing a reinforced wall, which provides a structural rigidity that can withstand the contractile force and pulsating force associated with the blood pressure in the aortic root. In many embodiments, the reinforced wall maintains the shape and functionality of the regenerated heart valve while bearing the stress from the blood pressure force.
[0127] In some embodiments, the surrounding wall is attached to the regenerated heart valve. In some embodiments, the surrounding wall is attached at the base of the regenerated heart valve. In some embodiments, the surrounding wall is not attached to the regenerated heart valve, but remains near the valve when implanted so that it surrounds the valve.
[0128] In several embodiments, the surrounding wall provides rigidity and support for the regenerated heart valve. In some embodiments, the surrounding wall can support the regenerated heart valve to withstand the force in the aorta, so that the heart valve can maintain the valve shape and continue to regenerate and grow after implantation. Therefore, in some embodiments, the surrounding wall has enough compressive strength to prevent the regenerated heart valve from collapsing due to the contractile force in the aortic root. Similarly, in some embodiments, the surrounding wall has enough fatigue strength so that the regenerated heart valve can withstand the pulsating pressure associated with contraction and diastole. As known in the art, the pressure in the aortic root can be about 120 systolic mmHg in a typical human, and can reach more than 150 systolic mmHg or even 180 systolic mmHg in individuals with severe hypertension. Therefore, in various embodiments, the regenerated heart valve can withstand a pressure of at least 100mmHg, 110mmHg, 120mmHg, 130mmHg, 140mmHg, 150mmHg, 160mmHg, 170mmHg or 180mmHg.
[0129] In many embodiments, the surrounding wall is biodegradable. According to various embodiments, a variety of synthetic biodegradable polymers can be used to construct the surrounding wall, including, but not limited to, polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB) and polycaprolactone (PCL). It should be understood that a variety of materials can be combined to construct the surrounding wall. In some embodiments, after implantation for a period of time, the surrounding wall is degraded, which can allow host cells to migrate into the wall and approach the wall so that the host cells can strengthen the natural aortic root wall after the implanted wall is degraded. When the regenerated valve is converted into host living tissue and adapted to the local environment (including bearing the force in the aortic root), the surrounding wall will no longer be needed. In various embodiments, the biodegradable surrounding wall will degrade within a period of 6 to 36 months. In some specific embodiments, the biodegradable surrounding wall will degrade within approximately 6, 12, 18, 24, 30 or 36 months. It will be appreciated that the selected material and thickness of the biodegradable surrounding wall may be selected so that the time period for degradation may be manipulated.
[0130] A number of embodiments relate to modifying the medial side of the surrounding wall to promote regeneration of regenerated heart valves and natural aortic root. In some embodiments, the surrounding wall is conformal to the micropattern on the medial side so that it promotes the formation of an endothelial-like tissue layer. In some embodiments, the surrounding wall is coated and / or impregnated with bioactive molecules on the medial side to promote regeneration. In some embodiments, the use of micropatterning and / or bioactive molecules prevents inappropriate pannus formation, which can result in destructive scar tissue at the implant site.
[0131] According to several embodiments, the inner side of the surrounding wall is conformal with a set of grooves and / or ridges to promote endothelialization and reduce pannus formation. Methods for micropatterning surfaces are known in the art, such as those described in U.S. Patent Application Publication No. 2015 / 0100118 to J.A. Benton, entitled "Methods for Directing Cell Migration Patterns in Biological Tissues," the disclosure of which is incorporated herein by reference. Note that polymeric surfaces (such as the inner side of the surrounding wall) can be micropatterned in a manner similar to biological tissues.
[0132] In several embodiments, the micropattern comprises a set of grooves and / or ridges on the surface, the size and offset distance of which is greater than the average size of fibroblasts or other cells associated with pannus formation. It is believed that the size of fibroblasts is in the range of 20 to 40 microns, more typically 10 to 20 microns. Therefore, in some embodiments, adjacent parallel grooves are offset by a distance of at least 10 microns, at least 20 microns, at least 30 microns, or at least 40 microns. And in some embodiments, each individual groove has a width and / or depth of at least 10 microns, at least 20 microns, at least 30 microns, or at least 40 microns. In some embodiments, the parallel grooves are curved. In some embodiments, a grid pattern of intersecting parallel grooves is used.
[0133] In many embodiments, the inner side of the surrounding wall is coated and / or impregnated with bioactive molecules to promote regeneration and differentiation within the native aortic root. Thus, extracellular growth factors, cytokines and / or ligands can be provided to stimulate regenerative growth and vascular differentiation. In some embodiments, the factors provided include (but are not limited to) vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), insulin-like growth factor 1 (IGF-1) and matrix-derived factor-1-α (SDF-1-α). In multiple embodiments, anti-inflammatory factors are provided with the regenerated tissue to reduce inflammation and immune-mediated destruction of the regenerated valve. In some embodiments, the anti-inflammatory factors to be provided include (but are not limited to) curcumin and flavonoids.
[0134] In a number of embodiments, various biological cells are incorporated into or coated on the inner side of the surrounding wall, which helps promote the regeneration and differentiation of the natural aortic root. A variety of cell sources can be used. In various embodiments, cell sources include, but are not limited to, mesenchymal stem cells (e.g., derived from bone marrow), cardiac progenitor cells, endothelial progenitor cells, adipose tissue, vascular tissue, cells derived from amniotic fluid, and cells differentiated from pluripotent stem cells. In some embodiments, vascular tissue is derived from peripheral arteries and / or umbilical veins, which can be used to isolate endothelial cells and myofibroblasts for regeneration tissue formulation. In some embodiments, pluripotent stem cells are induced into a pluripotent state from mature cells (e.g., fibroblasts). In several embodiments, cells are derived from individuals to be treated, which reduces concerns associated with allogeneic sources.
[0135] A number of embodiments relate to methods of delivering a surrounding wall and / or a regenerative valve to a deployment site. As understood in the art, the methods may be performed on any suitable recipient, including but not limited to a human, other mammal (e.g., a pig), a cadaver, or an anthropomorphic mannequin. Thus, the delivery methods include methods of treatment (e.g., treatment of a human subject) and methods of training and / or practice (e.g., performing the methods using an anthropomorphic mannequin that simulates the human vasculature). Delivery methods include but are not limited to open heart surgery and transcatheter delivery.
[0136] When a transcatheter delivery system is used, any suitable approach to the deployment site can be utilized, including, but not limited to, transfemoral, subclavian, transapical, or transaortic approaches. In several embodiments, a catheter comprising a surrounding wall and / or a regenerated valve is delivered to the deployment site via a guidewire. At the deployment site, according to many embodiments, the wall and / or the regenerated valve are released from the catheter and then expanded to a form in which the wall surrounds the regenerated heart valve. A variety of expansion mechanisms can be utilized, such as, for example, the use of an inflatable balloon, mechanical expansion, or a self-expanding device. Specific shape designs and radiopaque areas on the frame and / or on the covering can be used to monitor expansion and implementation.
[0137] The delivery and use of the circumferential wall and / or regenerative valve can be used in a variety of applications. In some embodiments, the circumferential wall and / or regenerative device is delivered to a site for valve replacement, particularly aortic valve replacement.
[0138] Regenerative heart valves
[0139] Several embodiments relate to the use of heart valves formed by regeneration, including leaflets. The regenerative tissue to be used to regenerate the heart valve can be any appropriate regenerative tissue formulation as understood in the art. In various embodiments, the regenerative tissue is formulated in vitro. In some embodiments, the regenerative tissue is autologous (e.g., produced from tissues and or cells of the individual to be treated). In some embodiments, the regenerative tissue is allogeneic (e.g., produced from a source other than the individual to be treated). When allogeneic tissue is used, appropriate measures may be required to reduce the immune reactivity and / or rejection of the tissue, according to some embodiments.
[0140] In various embodiments, the regenerated tissue is formulated to enable the regenerated heart valve to grow, adapt, and integrate within the aortic root after implantation. Growth and adaptation are particularly important for heart valve replacement in children, which can avoid the necessity of multiple valve replacement surgeries as the child grows. In some embodiments, the regenerated heart valve is formulated to resist thrombosis and pannus formation. In some embodiments, the regenerated heart valve is "trained" in a bioreactor system that simulates the physiological and mechanical pressures that occur in the aortic root.
[0141] According to several embodiments, regeneration tissue is formulated on the support so that the tissue grows into a suitable heart valve shape. In many embodiments, the support is biodegradable so that when implanted and / or in a short time after implantation, the support degradation leaves only regeneration tissue. As understood in the art, a variety of support matrices can be used. In some embodiments, synthetic polymers are used, such as (for example) polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB) and polycaprolactone (PCL). In some embodiments, a biomatrix is used, which can be formulated by a variety of biomolecules, including but not limited to collagen, fibrin, hyaluronic acid, alginate and chitosan. In some embodiments, decellularized extracellular matrix is used as a support. It should be understood that various support matrices can be combined and utilized according to various embodiments.
[0142] Many cell sources can be used to formulate regenerative tissue. In various embodiments, cell sources include, but are not limited to, mesenchymal stem cells (e.g., derived from bone marrow), cardiac progenitor cells, endothelial progenitor cells, adipose tissue, vascular tissue, cells derived from amniotic fluid, and cells differentiated from pluripotent stem cells (including embryonic stem cells). In some embodiments, vascular tissue is derived from peripheral arteries and / or umbilical veins, which can be used to isolate endothelial cells and myofibroblasts for regenerative tissue formulation. In some embodiments, pluripotent stem cells are induced into a pluripotent state from mature cells (e.g., fibroblasts). In several embodiments, cells are derived from individuals to be treated, which reduces concerns associated with allogeneic sources.
[0143] In various embodiments, bioactive molecules including regeneration and differentiation factors are provided with the regenerative tissue to stimulate host regeneration at the implantation site. Thus, extracellular growth factors, cytokines and / or ligands can be provided to stimulate regenerative growth and vascular differentiation. In some embodiments, the factors provided include, but are not limited to, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), insulin-like growth factor 1 (IGF-1) and matrix-derived factor-1-α (SDF-1-α). In multiple embodiments, anti-inflammatory factors are provided with the regenerative tissue to reduce inflammation and immune-mediated destruction of the regenerated valve. In some embodiments, the anti-inflammatory factors to be provided include, but are not limited to, curcumin and flavonoids.
[0144] In a plurality of embodiments, the regenerative heart valve will be inserted into the aortic root to replace the malfunctioning aortic valve, wherein the force associated with systolic and diastolic pressures is very strong and repeated. Because the regenerative heart valve is usually composed of soft tissue and has a high degree of plasticity, they lack sufficient rigidity to withstand strong pulsating pressures. Therefore, the newly implanted regenerative heart valve may be forced to collapse, causing serious damage and preventing the valve from correctly combining with the aortic root. Further growth and regeneration in the aortic root may also be inhibited, because the host cell will not have the ability to migrate and assimilate in the regenerative valve. Therefore, several embodiments relate to providing a reinforcing element, which provides the structural strength that can withstand the contractile force and pulsating force associated with the blood pressure in the aortic root. In many embodiments, the reinforcing element maintains the shape and functionality of the regenerative heart valve while bearing the stress from the blood pressure.
[0145] Principle of Equivalence
[0146] Although the above description contains many specific embodiments of the present invention, these should not be interpreted as limiting the scope of the present invention, but as an example of one embodiment thereof. Therefore, the scope of the present invention should not be determined by the exemplified embodiments, but by the appended claims and their equivalents.
Claims
1. An implantable device for heart valve replacement, comprising: A regenerated heart valve, the regenerated heart valve comprising regenerated tissue; a first ring structure adapted to be located at the base of the heart valve to provide support to the regenerated tissue so that when the heart valve is located at a replacement site, the regenerated tissue can grow and combine with native tissue while maintaining the valve shape of the heart valve, and One or more second ring structures are adapted to be provided along the commissures of the regenerated heart valve and located on the outflow side of the heart valve to provide support for the regenerated tissue so that when the heart valve is located at the replacement site, the regenerated tissue can grow and integrate with natural tissue while maintaining the valve shape of the heart valve.
2. The device of claim 1, further comprising a first tissue layer encapsulating the first ring structure, wherein the first tissue layer reduces exposure of the first ring structure to native surrounding tissue when positioned at a replacement site.
3. A device as described in claim 1 or 2, wherein the heart valve is an aortic valve and the first ring structure provides sufficient support to enable the regenerated tissue to grow in the presence of forces occurring in the native aortic root.
4. A device as described in claim 1 or 2, wherein the first ring structure is further adapted to expand as the heart valve ring expands.
5. The device of claim 1 or 2, wherein the first ring structure is segmented into at least one segment having two overlapping ends that allow expansion.
6. The device of claim 5, wherein the two overlapping ends are secured together using a pin on the first end and a receiving guide on the second end.
7. The apparatus of claim 6, wherein the pin has a pin head extending orthogonally from the first end, and the guide has a hollow portion configured to fit the pin head, and wherein the guide further has a hole allowing the pin to move in one direction, allowing both ends to move in opposite directions.
8. The device of claim 1 or 2, wherein the first ring structure is an overlapping coiled ring.
9. The device of claim 1 or 2, wherein the first ring structure is a compression ring helical spring.
10. The device of any one of claims 1-2 and 6-7, wherein the first ring structure is constructed of a biodegradable material.
11. The device of claim 10, wherein the biodegradable material is selected from the group consisting of polyglycolic acid (PGA), polylactic acid (PLA), poly-D-lactide (PDLA), polyurethane (PU), poly-4-hydroxybutyrate (P4HB) and polycaprolactone (PCL).
12. The device of claim 10, wherein the biodegradable material is designed to degrade within a time period selected from the group consisting of: 6, 12, 18, 24, 30, and 36 months.
13. The device of claim 10, wherein the first tissue layer is adapted to capture degradation particles of the first ring structure.
14. The device of any one of claims 1-2 and 6-7, wherein the first ring structure is constructed of a metallic material.
15. The device of claim 14, wherein the metal material is selected from the group consisting of stainless steel, cobalt-chromium alloy, titanium and titanium alloy.
16. The device of any one of claims 1-2, 6-7, 11-13 and 15, wherein the first ring structure is attached to the base of the heart valve, and wherein the attachment is provided by sutures or an adhesive.
17. The device of any one of claims 1-2, 6-7, 11-13 and 15, further comprising: A second tissue layer encapsulates the one or more second ring structures, wherein the second tissue layer reduces exposure of the one or more second ring structures to native surrounding tissue when positioned at the replacement site.
18. The device of claim 17, wherein the second ring structure is expandable.
19. The device of claim 1, wherein the first and second ring structures are encased within a tissue sleeve, and the tissue sleeve is formed from pericardial tissue derived from an animal source.
20. The device of claim 1, wherein the first and second ring structures are encased within a tissue sleeve, and wherein the tissue sleeve is formed from autologous tissue derived from the individual to be treated.
21. The device of any one of claims 1-2, 6-7, 11-13, 15 and 18, wherein the tissue of the regenerated heart valve is formed in vitro.
22. The device of any one of claims 1-2, 6-7, 11-13, 15 and 18, wherein the tissue of the regenerated heart valve is formed from autologous tissue derived from the individual to be treated.
23. The device of any one of claims 1-2, 6-7, 11-13, 15 and 18, wherein the tissue of the regenerated heart valve is grown as a biodegradable scaffold.
24. The device of claim 23, wherein the biodegradable scaffold is made of a material selected from the group consisting of collagen, fibrin, hyaluronic acid, alginate, decellularized extracellular matrix, and chitosan.
25. The device of claim 3, wherein the regenerative heart valve is trained in a bioreactor system that simulates the physiological and mechanical stresses that occur in the native aortic root.
26. The device of any one of claims 1-2, 6-7, 11-13, 15, 18 and 24-25, wherein the tissue for regenerating the heart valve is grown from a cell source selected from the group consisting of mesenchymal stem cells, cardiac progenitor cells, endothelial progenitor cells, adipose tissue, vascular tissue, amniotic fluid-derived cells and cells differentiated from pluripotent stem cells.
27. The device of claim 26, wherein the cell source is mesenchymal stem cells derived from human bone marrow.
28. The device of claim 26, wherein the cell source is vascular tissue derived from a peripheral artery or umbilical vein.
29. The device of any one of claims 1-2, 6-7, 11-13, 15, 18, 24-25, and 27-28, wherein the tissue of the regenerated heart valve is bound to a bioactive molecule.
30. The device of claim 29, wherein the bioactive molecule promotes regeneration and differentiation.
31. The device of claim 29, wherein the bioactive molecule is selected from the group consisting of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β), angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), insulin-like growth factor 1 (IGF-1), and stromal derived factor-1-α (SDF-l-α).
32. The device of claim 29, wherein the bioactive molecule reduces inflammation and immune-mediated destruction of the regenerated valve.
